By: Tomoaki Takei
Multinational pharma giant Eli Lilly’s Mounjaro (tirzepatide), the dual GIP/GLP-1 receptor agonist, is at the center of a rapidly escalating public health storm in East Asia. While clinically approved as a life-saving treatment for Type 2 diabetes, the drug has been effectively deified on social media as the ultimate cosmetic weight-los…
Keep reading with a 7-day free trial
Subscribe to Asia Sentinel to keep reading this post and get 7 days of free access to the full post archives.